ASO Author Reflections: Postoperative Carbohydrate Antigen 19-9 Levels Become a Reliable Biomarker for Establishing Intensity-Stratified Adjuvant Treatments in Pancreatic Ductal Adenocarcinoma-Reference-Cited by-同舟云学术

ASO Author Reflections: Postoperative Carbohydrate Antigen 19-9 Levels Become a Reliable Biomarker for Establishing Intensity-Stratified Adjuvant Treatments in Pancreatic Ductal Adenocarcinoma

Published:2023-10-31 Issue:1 Volume:31 Page:548-549
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Ariake Kyohei,Okada Takaho,Tsuchiya Haruyuki,Kuboki Daiki,Maemura Kimiya,Ichikawa Hidetaka,Tachibana Tomoyoshi,Akazawa Naoya,Abe Tomoya,Kakita Tetsuya,Oikawa Masaya,Tsuchiya Takashi

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-023-14506-z.pdf

Reference5 articles.

1. National Comprehensive Cancer Network. NCCN practice guidelines for pancreatic cancer, version 2. 2022. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed 1 Mar 2023.

2. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edn). In: Japanese Gastric Cancer Association, ed. Gastric Cancer. Tokyo: Kanehara-shuppan, 2023:1-25.

3. Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1–42.

4. Chatterjee D, Katz MH, Foo WC, et al. Prognostic significance of new AJCC tumor stage in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy. Am J Surg Pathol. 2017;41:1097–104.

5. Ariake K, Okada T, Tsuchiya H, et al. Postoperative carbohydrate antigen 19–9 level as a good indicator of ineffective response to the currently recommended S-1 adjuvant chemotherapy for pancreatic ductal adenocarcinoma: a single-center retrospective study. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-14440-0.